Danielle Jeddah
Danielle Jeddah has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Nicholas B Bevins
Department of Clinical Research, BirdRock Laboratories , San Diego, CA
2 shared publications- Andrea Forgacs
Clew Medical Ltd., Netanya, Israel
1 shared publication - Ari M. Lipsky
Department of Emergency Medicine, HaEmek Medical Center, Afula, Israel
1 shared publication - Arnaldo Mayer
Tel Aviv University
1 shared publication - Craig M. Lilly
Department of Medicine, University of Massachusetts Medical School, Worcester, MA
1 shared publication - Dana Hoffman
From the Sackler School of Medicine (S.F., M.G., D.J., D.H., R.B., A.M., E.K.), Tel-Aviv University, Tel-Aviv, Israel
1 shared publication
Latest Publications
- 11 July 2025
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 10 (5) , 1241-1253
Diagnostic Accuracy of Smartphone-Enabled Urinary Albumin-to-Creatinine Ratio Testing
Background: Albuminuria is an important biomarker for detecting chronic kidney disease (CKD), particularly in at-risk individuals. Advances in diagnostic technology have introduced home-use, semiquantitative testing methods such as the FDA-cleared Minuteful Kidney Test (MKT). This study compares the diagnostic accuracy of the MKT to the Beckman Coulter AU 480 analyzer, a standard laboratory quantitative method, for detecting albuminuria in individuals with or at risk for CKD. Methods: Urine samples were obtained from individuals with risk factors for kidney damage. Each sample was analyzed for the urinary albumin-to-creatinine ratio (uACR) using both the MKT and the laboratory standard method. Albuminuria was classified according to KDIGO guidelines: A1 (uACR 300 mg/g, “severely increased”). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of MKT were calculated against the laboratory standard. Results: Out of 615 collected urine samples, 555 met inclusion criteria. Albuminuria (uACR >30 mg/g) was detected in 24.9% of samples using the laboratory method (95% CI: 21.3%–28.5%). The MKT demonstrated a sensitivity of 96.4%, specificity of 84.2%, NPV of 98.6%, and PPV of 66.8%. MKT accurately categorized 85.6% of samples into the KDIGO albuminuria categories A1, A2, and A3, identifying 100% of laboratory-confirmed A3 samples as abnormal. Conclusions: The MKT shows high sensitivity, exceeding the guideline-required threshold (>85%, P < 0.001), and acceptable specificity for detecting albuminuria in high-risk populations. This device offers the potential to improve CKD detection and management and facilitate early intervention in primary care and community settings, where accurate rule-out capabilities are essential.
- 11 July 2025
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 10 (5) , 1241-1253
Diagnostic Accuracy of Smartphone-Enabled Urinary Albumin-to-Creatinine Ratio Testing
Background: Albuminuria is an important biomarker for detecting chronic kidney disease (CKD), particularly in at-risk individuals. Advances in diagnostic technology have introduced home-use, semiquantitative testing methods such as the FDA-cleared Minuteful Kidney Test (MKT). This study compares the diagnostic accuracy of the MKT to the Beckman Coulter AU 480 analyzer, a standard laboratory quantitative method, for detecting albuminuria in individuals with or at risk for CKD. Methods: Urine samples were obtained from individuals with risk factors for kidney damage. Each sample was analyzed for the urinary albumin-to-creatinine ratio (uACR) using both the MKT and the laboratory standard method. Albuminuria was classified according to KDIGO guidelines: A1 (uACR 300 mg/g, “severely increased”). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of MKT were calculated against the laboratory standard. Results: Out of 615 collected urine samples, 555 met inclusion criteria. Albuminuria (uACR >30 mg/g) was detected in 24.9% of samples using the laboratory method (95% CI: 21.3%–28.5%). The MKT demonstrated a sensitivity of 96.4%, specificity of 84.2%, NPV of 98.6%, and PPV of 66.8%. MKT accurately categorized 85.6% of samples into the KDIGO albuminuria categories A1, A2, and A3, identifying 100% of laboratory-confirmed A3 samples as abnormal. Conclusions: The MKT shows high sensitivity, exceeding the guideline-required threshold (>85%, P < 0.001), and acceptable specificity for detecting albuminuria in high-risk populations. This device offers the potential to improve CKD detection and management and facilitate early intervention in primary care and community settings, where accurate rule-out capabilities are essential.
- Open Access
Diagnostic Accuracy of a Smartphone-Enabled Urinary Albumin-to-Creatinine Ratio Test for Detecting Chronic Kidney Disease Among At-Risk Populations
Objective To evaluate the diagnostic accuracy of the FDA-cleared Minuteful Kidney Test (MKT), a home-based semi-quantitative urine albumin-to-creatinine ratio (uACR) test, compared to the Beckman Coulter AU 480 analyzer, a standard laboratory quantitative method, for detecting albuminuria in individuals with or at risk for chronic kidney disease (CKD). Methods Urine samples were obtained from individuals with risk factors for kidney damage. Each sample was analyzed for uACR using both the MKT and the laboratory standard method. Albuminuria was classified according to KDIGO guidelines: A1 (uACR ≤30 mg/g, “Normal to mildly increased”), A2 (uACR 30-300 mg/g, “Moderately increased”), and A3 (uACR ≥300 mg/g, “Severely increased”). Sensitivity, specificity, PPV, and NPV of MKT were calculated against the laboratory standard. Results Out of 615 collected urine samples, 555 met inclusion criteria. Albuminuria (uACR ≥30 mg/g) was detected in 24.9% of samples using the laboratory method (95% CI, 21.3–28.5%). The MKT demonstrated a sensitivity of 96.4%, specificity of 84.2%, NPV of 98.6%, and PPV of 66.8%. The test accurately categorized 85.6% of samples into the KDIGO albuminuria categories A1, A2, and A3, accurately identifying 100% of laboratory-confirmed A3 samples as abnormal. Conclusions The Minuteful Kidney Test shows high sensitivity, exceeding the guideline-required threshold (>85%, P<0.001), and robust specificity for detecting albuminuria in high-risk populations. This device offers potential to improve CKD screening and management and facilitate early intervention in primary care and community settings, where accurate rule-out capabilities are essential.
Open AccessDiagnostic Accuracy of a Smartphone-Enabled Urinary Albumin-to-Creatinine Ratio Test for Detecting Chronic Kidney Disease Among At-Risk Populations
Objective To evaluate the diagnostic accuracy of the FDA-cleared Minuteful Kidney Test (MKT), a home-based semi-quantitative urine albumin-to-creatinine ratio (uACR) test, compared to the Beckman Coulter AU 480 analyzer, a standard laboratory quantitative method, for detecting albuminuria in individuals with or at risk for chronic kidney disease (CKD). Methods Urine samples were obtained from individuals with risk factors for kidney damage. Each sample was analyzed for uACR using both the MKT and the laboratory standard method. Albuminuria was classified according to KDIGO guidelines: A1 (uACR ≤30 mg/g, “Normal to mildly increased”), A2 (uACR 30-300 mg/g, “Moderately increased”), and A3 (uACR ≥300 mg/g, “Severely increased”). Sensitivity, specificity, PPV, and NPV of MKT were calculated against the laboratory standard. Results Out of 615 collected urine samples, 555 met inclusion criteria. Albuminuria (uACR ≥30 mg/g) was detected in 24.9% of samples using the laboratory method (95% CI, 21.3–28.5%). The MKT demonstrated a sensitivity of 96.4%, specificity of 84.2%, NPV of 98.6%, and PPV of 66.8%. The test accurately categorized 85.6% of samples into the KDIGO albuminuria categories A1, A2, and A3, accurately identifying 100% of laboratory-confirmed A3 samples as abnormal. Conclusions The Minuteful Kidney Test shows high sensitivity, exceeding the guideline-required threshold (>85%, P<0.001), and robust specificity for detecting albuminuria in high-risk populations. This device offers potential to improve CKD screening and management and facilitate early intervention in primary care and community settings, where accurate rule-out capabilities are essential.
- 12 August 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (10) , 1878-1883
Correlation between 2D and 3D Fetal Brain MRI Biometry and Neurodevelopmental Outcomes in Fetuses with Suspected Microcephaly and Macrocephaly
BACKGROUND AND PURPOSE: Definitions of fetal microcephaly and macrocephaly are debatable. A better understanding of their long-term prognoses would help guide parental education and counseling. This study aimed to explore the correlation between 2D and 3D fetal brain MR imaging biometry results and the long-term neurodevelopmental outcomes. MATERIALS AND METHODS: This analysis is a historical cohort study. Fetal brain biometry was measured on 2D and 3D MR imaging using a volumetric MR imaging semiautomated algorithm. We measured and assessed the following brain structures: the supratentorial brain volume and cerebellar volume and cerebellar volume/supratentorial brain volume ratio, in addition to commonly used 2D brain MR imaging biometric variables, including occipitofrontal diameter, biparietal diameter, and transcerebellar diameter. Microcephaly was defined as ≤ 3rd percentile; and macrocephaly, as ≥ 97th percentile, corresponding to −2 SDs and +2 SDs. The neurodevelopmental outcome of this study cohort was evaluated using the Vineland-II Adaptive Behavior Scales, and the measurements were correlated to the Vineland standard scores. RESULTS: A total of 70 fetuses were included. No significant correlation was observed between the Vineland scores and either the supratentorial brain volume, cerebellar volume, or supratentorial brain volume/cerebellar volume ratio in 3D or 2D MR imaging measurements, after correction for multiple comparisons. No differences were found among fetuses with macrocephaly, normocephaly, or microcephaly regarding the median Vineland standard scores. CONCLUSIONS: Provided there is normal brain structure on MR imaging, the developmental milestone achievements in early years are unrelated to 2D and 3D fetal brain MR imaging biometry, in the range of measurements depicted in this study.
- 12 August 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (10) , 1878-1883
Correlation between 2D and 3D Fetal Brain MRI Biometry and Neurodevelopmental Outcomes in Fetuses with Suspected Microcephaly and Macrocephaly
BACKGROUND AND PURPOSE: Definitions of fetal microcephaly and macrocephaly are debatable. A better understanding of their long-term prognoses would help guide parental education and counseling. This study aimed to explore the correlation between 2D and 3D fetal brain MR imaging biometry results and the long-term neurodevelopmental outcomes. MATERIALS AND METHODS: This analysis is a historical cohort study. Fetal brain biometry was measured on 2D and 3D MR imaging using a volumetric MR imaging semiautomated algorithm. We measured and assessed the following brain structures: the supratentorial brain volume and cerebellar volume and cerebellar volume/supratentorial brain volume ratio, in addition to commonly used 2D brain MR imaging biometric variables, including occipitofrontal diameter, biparietal diameter, and transcerebellar diameter. Microcephaly was defined as ≤ 3rd percentile; and macrocephaly, as ≥ 97th percentile, corresponding to −2 SDs and +2 SDs. The neurodevelopmental outcome of this study cohort was evaluated using the Vineland-II Adaptive Behavior Scales, and the measurements were correlated to the Vineland standard scores. RESULTS: A total of 70 fetuses were included. No significant correlation was observed between the Vineland scores and either the supratentorial brain volume, cerebellar volume, or supratentorial brain volume/cerebellar volume ratio in 3D or 2D MR imaging measurements, after correction for multiple comparisons. No differences were found among fetuses with macrocephaly, normocephaly, or microcephaly regarding the median Vineland standard scores. CONCLUSIONS: Provided there is normal brain structure on MR imaging, the developmental milestone achievements in early years are unrelated to 2D and 3D fetal brain MR imaging biometry, in the range of measurements depicted in this study.
- Open Access
- 31 July 2021
- Published by The Korean Society of Medical Informatics in Healthcare Informatics Research
- Vol. 27 (3) , 241-248
Validation of an Automatic Tagging System for Identifying Respiratory and Hemodynamic Deterioration Events in the Intensive Care Unit
Objectives: Predictive models for critical events in the intensive care unit (ICU) might help providers anticipate patient deterioration. At the heart of predictive model development lies the ability to accurately label significant events, thereby facilitating the use of machine learning and similar strategies. We conducted this study to establish the validity of an automated system for tagging respiratory and hemodynamic deterioration by comparing automatic tags to tagging by expert reviewers.Methods: This retrospective cohort study included 72,650 unique patient stays collected from Electronic Medical Records of the University of Massachusetts’ eICU. An enriched subgroup of stays was manually tagged by expert reviewers. The tags generated by the reviewers were compared to those generated by an automated system.Results: The automated system was able to rapidly and efficiently tag the complete database utilizing available clinical data. The overall agreement rate between the automated system and the clinicians for respiratory and hemodynamic deterioration tags was 89.4% and 87.1%, respectively. The automatic system did not add substantial variability beyond that seen among the reviewers.Conclusions: We demonstrated that a simple rule-based tagging system could provide a rapid and accurate tool for mass tagging of a compound database. These types of tagging systems may replace human reviewers and save considerable resources when trying to create a validated, labeled database used to train artificial intelligence algorithms. The ability to harness the power of artificial intelligence depends on efficient clinical validation of targeted conditions; hence, these systems and the methodology used to validate them are crucial.
- 31 July 2021
- Published by The Korean Society of Medical Informatics in Healthcare Informatics Research
- Vol. 27 (3) , 241-248
Open AccessValidation of an Automatic Tagging System for Identifying Respiratory and Hemodynamic Deterioration Events in the Intensive Care Unit
Objectives: Predictive models for critical events in the intensive care unit (ICU) might help providers anticipate patient deterioration. At the heart of predictive model development lies the ability to accurately label significant events, thereby facilitating the use of machine learning and similar strategies. We conducted this study to establish the validity of an automated system for tagging respiratory and hemodynamic deterioration by comparing automatic tags to tagging by expert reviewers.Methods: This retrospective cohort study included 72,650 unique patient stays collected from Electronic Medical Records of the University of Massachusetts’ eICU. An enriched subgroup of stays was manually tagged by expert reviewers. The tags generated by the reviewers were compared to those generated by an automated system.Results: The automated system was able to rapidly and efficiently tag the complete database utilizing available clinical data. The overall agreement rate between the automated system and the clinicians for respiratory and hemodynamic deterioration tags was 89.4% and 87.1%, respectively. The automatic system did not add substantial variability beyond that seen among the reviewers.Conclusions: We demonstrated that a simple rule-based tagging system could provide a rapid and accurate tool for mass tagging of a compound database. These types of tagging systems may replace human reviewers and save considerable resources when trying to create a validated, labeled database used to train artificial intelligence algorithms. The ability to harness the power of artificial intelligence depends on efficient clinical validation of targeted conditions; hence, these systems and the methodology used to validate them are crucial.